New combo may turn inoperable esophageal cancer into operable disease
NCT ID NCT07549100
First seen Apr 29, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study tests whether a combination of tislelizumab (an immunotherapy) and chemotherapy can shrink advanced esophageal cancer enough to allow surgery. About 30 adults with initially inoperable tumors will receive the treatment for 2-4 cycles. The main goal is to see how many become eligible for surgery, with secondary goals of measuring tumor response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Hospital
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.